Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This study found that new curcumin analogues, such as ASC-J9, can inhibit prostate cancer cell growth by promoting androgen receptor degradation.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

This study reports that new compounds with anti-androgenic effects were found to counteract testosterone in animals without significant estrogenic activity, indicating potential for managing androgen-related conditions.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This Mendelian randomization study reports that lifelong increased free testosterone in males was associated with improved bone mineral density and body composition but increased risks of prostate cancer, hypertension, and several other conditions.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

This review found that androgenetic alopecia may be associated with increased risks of cardiovascular disease, metabolic disorders, and mental health impacts, suggesting its potential as a biomarker for systemic conditions.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This case report found that a dog's progressive alopecia and prostatitis were caused by ingesting a transdermal estradiol cream, emphasizing the need to identify exogenous estrogen sources during evaluation.

This study found that men who began balding at age 20 were twice as likely to develop prostate cancer later in life compared to those who did not experience early hair loss.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

Corni Fructus extract may help manage benign prostatic hyperplasia by reducing prostate cell growth and inflammation.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

In this study, kolaviron and quercetin were found to reverse elevated biomarkers associated with testosterone-induced benign prostatic hyperplasia in Wistar rats, with both treatments effectively increasing HDL-c levels, though quercetin did not significantly affect triglyceride levels.

This study from Athens, Greece observed that urban living may increase prostate cancer risk, while early adulthood sexual activity might inversely relate to this risk.

In this study from Athens, Greece, there was no evidence linking prostate cancer with vertex baldness, smoking, coffee, or alcohol, but urban living and early adulthood sexual activity may influence risk.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

This review examines sulforaphane's interactions with hormone-mediated health conditions, focusing on gender-specific health issues, but reports no new original research findings.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

This study found that men with androgenetic alopecia at age 20 years may have a higher risk of developing aggressive prostate cancer, particularly advanced stage disease.

This study observed that adherence to finasteride treatment in patients with benign prostatic hyperplasia at a clinic in Tepic Nayarit had not been previously evaluated in Mexico.